Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C1647
http://purl.obolibrary.org/obo/NCIT_C1647
|
|---|---|
| Preferred Name | Trastuzumab |
| Definitions |
A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04) |
|---|---|
| prefLabel | Trastuzumab
|
| label | Trastuzumab
|
| PDQ_Closed_Trial_Search_ID | 42265
|
| code | C1647
|
| Has_Target | |
| prefixIRI | NCIT:C1647
|
| in_subset |
See more
See less
|
| Display_Name | Trastuzumab
|
| Preferred_Name | Trastuzumab
|
| FDA_UNII_Code | P188ANX8CK
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Trastuzumab
|
| CAS_Registry | 180288-69-1
|
| NSC Number | 688097
|
| NCI_Drug_Dictionary_ID | 42265
|
| Legacy Concept Name | Trastuzumab
|
| type | |
| ALT_DEFINITION | A drug used alone or with other drugs to treat certain types of breast cancer, stomach cancer, and gastroesophageal junction cancer that are HER2 positive. It is also being studied in the treatment of other types of cancer. Trastuzumab binds to a protein called HER2, which is found on some cancer cells. This may help the immune system kill cancer cells. Trastuzumab is a type of monoclonal antibody and a type of HER2 receptor antagonist.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 42265
|
| Accepted_Therapeutic_Use_For | Breast cancer overexpressing HER2 protein; Pancreatic cancer overexpressing p185HER2
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
Immunologic Factor
|
| UMLS_CUI | C0728747
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |